Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Alzheimer Disease, Early Onset: early-phase trial registry

5 of 12 indexed Alzheimer Disease, Early Onset trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 5 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Alzheimer Disease, Early Onset: 12 US clinical trials tracked, 5 recruiting.

Alzheimer Disease, Early Onset is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Pain Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition alzheimer-disease-early-onset

OPEN 5 | RECR 42% | LATE 0 | EARLY 5 | RANK #1429 | SPON 1

Nearest open-share peer: Adiposity (42% recruiting · 12 trials)

Alzheimer Disease, Early (th…42%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Alzheimer Disease, Early Onset

Alzheimer Disease, Early Onset lists 5 open slots (42% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Alzheimer Disease, Early Onset on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Alzheimer Disease, Early Onset is recruiting below its size-band peers.

    5 of 12 indexed trials (41.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Alzheimer Disease, Early Onset trials is spread across many organizations.

    Pain Therapeutics accounts for 1 of 12 trials (8.3%). 12 distinct sponsors appear on at least one study for this condition label.

  3. Typical Alzheimer Disease, Early Onset enrolment sits around 90 participants.

    Median target enrolment is 90 among the 12 trials that report a genuine target (sentinel values excluded). 7 of those (58.3%) plan for fewer than 100 participants.

  4. Alzheimer Disease, Early Onset research is mostly interventional.

    10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22

Open and recent trials

12 total, page 1 of 1

RECRUITING 10,000 participants

NYSCF Scientific Discovery Biobank

New York Stem Cell Foundation Research Institute

NCT06203106

RECRUITING NA 90 participants

Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease

Johns Hopkins University

NCT04122001

RECRUITING NA 60 participants

Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study

Indiana University

NCT05573490

RECRUITING NA 50 participants

Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy

Massachusetts Institute of Technology

NCT05655195

RECRUITING Phase 1 35 participants

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

Butler Hospital

NCT04500847

ACTIVE NOT RECRUITING NA 670 participants

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)

Cognito Therapeutics

NCT05637801

ACTIVE NOT RECRUITING Phase 2 310 participants

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

Bristol-Myers Squibb

NCT06268886

ACTIVE NOT RECRUITING Phase 1 144 participants

PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

ProMis Neurosciences

NCT06750432

ACTIVE NOT RECRUITING NA 60 participants

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

Mayo Clinic

NCT02740634

ACTIVE NOT RECRUITING Phase 2 48 participants

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

Washington University School of Medicine

NCT04685590

COMPLETED 4,884 participants

Genetic Studies in Familial Dementia

University of Miami

NCT04680013

COMPLETED Phase 1 24 participants

A Safety Study of PTI-125 in Healthy Volunteers

Pain Therapeutics

NCT03784300

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2

Named interventions

Most-linked intervention names on Alzheimer Disease, Early Onset records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
200 mg PTI-125 Drug
1 trials
100 mg PTI-125 Drug
1 trials
50 mg PTI-125 Drug
1 trials
PMN310 Drug
1 trials
C-11 PiB Drug
1 trials
Sensory Stimulation System (GS120) - Sham Device
1 trials
Sensory Stimulation System (GS120) - Active Device
1 trials

US sites by state

Facility locations filed on Alzheimer Disease, Early Onset trials. A trial with sites in several states counts in each.

California 4 trials
Florida 3 trials
New York 2 trials
North Carolina 2 trials
Massachusetts 2 trials
Arizona 2 trials
Texas 1 trials
Rhode Island 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Alzheimer Disease, Early Onset page

12 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 5 Alzheimer Disease, Early Onset trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Pain Therapeutics sponsors the most Alzheimer Disease, Early Onset trials on record, review their full trial history before evaluating a specific study. See Pain Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer Disease, Early Onset condition card totals 12 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.